Consensus MacroGenics, Inc.

Equities

MGNX

US5560991094

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
4.26 ^USD	0.00%		-4.27%	-55.72%

May. 10	Sector Update: Health Care Stocks Higher Late Afternoon	MT
May. 10	Sector Update: Health Care	MT

Evolution of the average Target Price on MacroGenics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

21bcfcf082a6ce1878ccfd6241d.Oqa4kCi1GgP4aIuadSLlQd8xWabJUhcRcZJFm4z6UcQ.F83s-233dFrKXOrjIGqdNJUJH8SHMGB9M-cjouC7OKZWy4vdZ-RfYLsBxg~3a70b636b67760d20a63bf07d8ef405b

Analyst Recommendations on MacroGenics, Inc.

BMO Downgrades MacroGenics to Market Perform From Outperform, Price Target at $8	May. 10	MT
Stifel Downgrades MacroGenics to Hold	May. 10	MT
TD Cowen Downgrades MacroGenics to Hold From Buy	May. 10	MT
B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target	Apr. 26	MT
TD Cowen Upgrades MacroGenics to Buy From Hold	Apr. 09	MT
JMP Securities Adjusts Price Target on MacroGenics to $22 From $16, Maintains Market Outperform Rating	Mar. 11	MT
HC Wainwright Adjusts Price Target on MacroGenics to $16 From $14, Maintains Neutral Rating	Mar. 11	MT
Stifel Adjusts Price Target on MacroGenics to $29 From $17, Keeps Buy Rating	Mar. 08	MT
BMO Capital Adjusts Price Target on MacroGenics to $24 From $18, Maintains Outperform Rating	Mar. 08	MT
BTIG Adjusts Price Target on MacroGenics to $24 From $12, Maintains Buy Rating	Mar. 04	MT
Barclays Raises Price Target on MacroGenics to $23 From $12, Maintains Overweight Rating	Feb. 29	MT
HC Wainwright Downgrades MacroGenics to Neutral From Buy, Adjusts Price Target to $14 From $12	Feb. 14	MT
JMP Securities Adjusts MacroGenics' Price Target to $16 From $10, Maintains Market Outperform Rating	Jan. 24	MT
Citigroup Upgrades MacroGenics to Buy From Neutral, Raises Price Target to $13 From $7	Dec. 20	MT
HC Wainwright Cuts MacroGenics' Price Target to $12 From $14, Keeps Buy Rating	Nov. 13	MT
Guggenheim Upgrades MacroGenics to Buy From Neutral, Price Target is $12	Nov. 07	MT
JMP Securities Adjusts Price Target on MacroGenics to $10 From $8, Maintains Market Outperform Rating	23-05-11	MT
BTIG Adjusts Price Target on MacroGenics to $12 From $6, Maintains Buy Rating	23-03-21	MT
HC Wainwright Adjusts MacroGenics Price Target to $14 From $12, Maintains Buy Rating	23-03-20	MT
Guggenheim Downgrades MacroGenics to Neutral From Buy	23-03-17	MT
Citigroup Downgrades MacroGenics to Neutral From Buy, Adjusts Price Target to $7 From $16	22-11-23	MT
Cowen Downgrades MacroGenics to Market Perform From Outperform	22-11-22	MT
HC Wainwright Adjusts Price Target on MacroGenics to $12 From $11, Maintains Buy Rating	22-11-07	MT
HC Wainwright Adjusts MacroGenics' Price Target to $11 From $10, Maintains Buy Rating	22-10-18	MT
HC Wainwright Adjusts MacroGenics' Price Target to $10 from $35, Maintains Buy Rating	22-09-12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.26 USD

Average target price

13 USD

Spread / Average Target

+205.16%

High Price Target

24 USD

Spread / Highest target

+463.38%

Low Price Target

7 USD

Spread / Lowest Target

+64.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MacroGenics, Inc.

BMO Capital
Stifel Nicolaus
TD Cowen
B. Riley
JMP Securities
HC Wainwright
BTIG
Barclays
Citigroup
Guggenheim
Cowen
SVB Securities LLC
Morgan Stanley
SVB Leerink
SMBC Nikko
Wedbush
Credit Suisse

Ratings for MacroGenics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar